World Pharmaceutical Frontiers’ Post

🚀 Breaking news in the pharma world! Boehringer Ingelheim has acquired Nerio Therapeutics for up to $1.3 billion, significantly bolstering our immuno-oncology pipeline. This acquisition includes Nerio’s advanced preclinical program, which will be a cornerstone in developing innovative cancer treatments. 💡 Nerio Therapeutics, known for its pioneering work with phosphatases, brings to the table novel checkpoint inhibitors that expand our repertoire of potential cancer therapies. As Paola Casarosa, a member of our board of managing directors, stated, this move creates a broad panel of exciting new cancer treatment combination opportunities. 🧬 We’re thrilled to integrate Nerio’s small molecule PTPN1/N2 inhibitors into our portfolio. These inhibitors are designed to activate the immune system to combat cancer cells, offering a first-in-class opportunity with superior drug-like properties. This acquisition aligns perfectly with our mission to extend the benefits of immuno-oncology to more patients, potentially providing single-agent therapy solutions. 👏 A big shoutout to Sanford Madigan, co-founder and CEO of Nerio Therapeutics, and his team for their groundbreaking work. We’re excited to continue this journey together and unlock the full potential of these compounds in the fight against cancer. #BoehringerIngelheim #NerioTherapeutics #ImmunoOncology #CancerResearch #PharmaInnovation #Healthcare

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics